Teva Comments on Clarithromycin ER Preliminary Injunction

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Northern Illinois has granted Abbott's motion for a preliminary injunction related to Teva's generic Clarithromycin Extended Release Tablets pending a trial on the merits or further court order. The injunction is based on Abbott's enforcement of one extended release formulation patent that Teva has asserted are invalid.

Teva intends to seek an expedited appeal to the United States Court of Appeals for the Federal Circuit.

Teva's Clarithromycin Extended Release Tablets are the AB-rated generic equivalent of Abbott's macrolide antibiotic Biaxin(R) XL Filmtabs(R).

Due to the postponement of a commercial launch of Clarithromycin Extended Release Tablets, Teva expects its earnings for the second quarter ended June 30, 2005 to be reduced by approximately 4 cents. The Company will continue to evaluate its expectations for the year in light of this decision.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe.

Related Articles

• ORBOTECH Receives Injunction in its Patent Infringement Suit against Camtek
  20 May 2005